ClinicalTrials.Veeva

Menu

Total Intravenous Anesthesia (TIVA)/Sevoflurane Initiated Intravenous Anesthesia (SIIVA) in Pediatric Patients

Wake Forest University (WFU) logo

Wake Forest University (WFU)

Status

Enrolling

Conditions

Extubation

Treatments

Other: Sevoflurane initiated intravenous anesthesia (SIIVA)
Other: Total intravenous anesthesia (TIVA)

Study type

Observational

Funder types

Other

Identifiers

NCT05837936
IRB00092312

Details and patient eligibility

About

Because Propofol is the primary "anesthetic agent," and inhalational agents remain in trace quantities at the end of the procedure Sevoflurane initiated intravenous anesthesia (SIIVA) or not present at all Total intravenous anesthesia (TIVA) it is likely that different criteria may be predictive of extubation success in these patients compared to inhalational anesthesia.

Full description

This is because these anesthetic regimens have different pharmacologic mechanisms of actions, and therefore interact with central nervous system in different ways leading to potentially the need for different extubation criteria in patients receiving TIVA or SIIVA. Additionally, intravenous agents likely have less of an effect on airway reflexes and ventilation at light levels of anesthesia. This study is proposing an observational study to examine the predictive value of various extubation criteria in the setting of SIIVA and TIVA.

Enrollment

600 estimated patients

Sex

All

Ages

Under 9 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pediatric patients <10 years of age
  • Undergoing elective or emergency surgery with planned airway instrumentation with an endotracheal tube (ETT)
  • Patients having general anesthesia with a planned SIIVA or TIVA technique
  • Patients with an end tidal agent concentration of Sevoflurane<0.1% at the time of emergence and extubation
  • following sevoflurane induction to place IV

Exclusion criteria

  • History of home oxygen use or ventilator dependence
  • Patients with cyanotic congenital heart disease
  • Patients undergoing anesthesia for imaging procedures alone
  • Patients intended to be managed with supraglottic airway
  • Patients having an anesthesia time < 30 minutes
  • Monitored Anesthesia Care (not general anesthesia)
  • Patients with contraindication to receiving Propofol (i.e. mitochondrial myopathy)

Trial design

600 participants in 2 patient groups

Total intravenous anesthesia (TIVA)
Description:
TIVA is achieved without inhalational agents and may be performed in cases where patients have an intravenous line in place prior to induction of anesthesia
Treatment:
Other: Total intravenous anesthesia (TIVA)
Sevoflurane initiated intravenous anesthesia (SIIVA)
Description:
SIIVA is a modification of TIVA in the setting where a patient does not tolerate the insertion of an intravenous line prior to induction of anesthesia. The patient undergoes induction of anesthesia with sevoflurane and transition to Propofol IV anesthesia for maintenance once the intravenous line is in place and discontinues the inhalational agent, sevoflurane.
Treatment:
Other: Sevoflurane initiated intravenous anesthesia (SIIVA)

Trial contacts and locations

2

Loading...

Central trial contact

Lynne Harris, BSN; Wes Templeton, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems